Spinal and Brain Metastases: Prognostic Factors and Treatment Landscape

Metastatic spread to the central nervous system (brain mets) and vertebral column (spinal mets) signifies advanced systemic cancer. Prognosis varies widely.

Survival Estimates (Historical, Untreated/treated)

• Brain mets: Median OS 6–12 months (whole-brain RT era); selected patients with oligometastases + SRS + systemic therapy → 2–5+ years.
• Spinal mets: Median OS 6–18 months; ambulatory at diagnosis + radiosensitive histology → longer.

Key Prognostic Indices

• GPA (Graded Prognostic Assessment) for brain mets: Age, KPS, # mets, extracranial control, histology (lung, breast, melanoma, RCC, GI). Score 0–4 → median OS 3–25 months.
• Tokuhashi / Tomita / SORG scores for spinal mets: Incorporate primary type, visceral mets, bone mets, KPS, neurologic status.

Treatment Modalities

Modality	Brain Mets	Spinal Mets
Surgery	Single accessible lesion >3 cm, mass effect, tissue diagnosis	Instability (SINS), cord compression, radioresistant tumor, tissue dx
SRS (Stereotactic Radiosurgery)	1–4 mets <3 cm (standard); up to 10–15 in select centers	1–3 vertebral segments; postoperative cavity boost
WBRT (Whole-Brain RT)	Multiple mets, leptomeningeal, palliative	Rare (field too large)
Systemic Therapy	Crosses BBB variably: TKIs (EGFR, ALK, HER2), immunotherapy (melanoma, NSCLC), ADCs	Same; palliative for pain/progression
Vertebroplasty/Kyphoplasty	—	Painful compression fracture without cord compression

Multidisciplinary Spine Tumor Board

Essential for complex cases: Neurosurgery, radiation oncology, medical oncology, interventional radiology, palliative care, rehab.

Clinical trials (e.g., SRS + immunotherapy, targeted therapy for driver mutations) offer best hope for extended survival.